| Study characteristics |
| Methods |
To explore whether financial conflicts of interest were associated with greater probability of endorsement of specific anticancer drugs. Clinical guidelines on anticancer drugs for breast, colorectal, lung, and prostate cancers published between January 2003 and October 2013 |
| Data |
50 clinical guidelines (91 clinical guidelines included in the study, but not all had data available in a format for inclusion in analysis) |
| Comparisons |
Clinical guidelines with financial conflicts of interest (defined as at least one authors with employment, stock ownership, participation in speakers bureaus, consultancy, honoraria, research funding, and expert testimony) and clinical guidelines without financial conflicts of interest |
| Outcomes |
Recommendations (favourable recommendations defined as endorsement of a drug) |
| Funding source |
Funding source not described |
| Declaration of conflicts of interest |
BS (eight author) has received honoraria from Astellas, Janssen Oncology, Novartis, and Sanofi, and has a consulting or advisory role at Astellas, Sanofi, and Janssen Oncology |
| Notes |
|
| Risk of bias |
| Item |
Authors' judgement |
Support for judgement |
| Adequate document inclusion process |
No |
Only one author assessed clinical guidelines for inclusion (according to personal correspondence with corresponding author) |
| Adequate coding of conflicts of interest |
No |
Only one author coded each clinical guideline |
| Adequate coding of recommendations |
No |
Only one author coded the recommendations of each clinical guideline (according to personal correspondence with corresponding author) |
| Adequate dealing with confounding |
No |
Compared clinical guidelines of different cancer drugs used for different types of cancers |
